Adavosertib (AZD1775) with Gemcitabine and Radiation for Locally Advanced Pancreatic Cancer: An Interview with Kyle C. Cuneo, MD

Pancreatic cancer is one of the most aggressive forms of cancer, and owing to limited treatment options, it has one of the lowest survival rates. While patients are commonly treated with radiation therapy, there is a need to develop alternative treatment options that can improve the efficacy of radiation, reduce tumor progression, and increase survival. In a recent study, Kyle C. Cuneo, MD, and colleagues evaluated the safety and tolerability of adavosertib (AZD1775), an inhibitor of the Wee1 ki...
Continue reading

RABL3 Gene Mutation Linked to Hereditary Pancreatic Cancer

Researchers have determined that an inherited mutation in the RABL3 gene increases the risk of pancreatic cancer. One of the most aggressive malignancies, pancreatic cancer has limited treatment options and a low survival rate. While approximately 10% of patients exhibit a hereditary pattern, with multiple cases in a single family, it was until now unclear which genes predispose individuals to developing pancreatic cancer. Researchers led by first author Sahar Nissim, MD, PhD, a cancer geneticis...
Continue reading

Perlecan Enables Pancreatic Cancer to Spread, Resist Chemo

Researchers have determined that some pancreatic tumors can remodel their environments when their fibroblasts, cells that comprise connective tissue, produce high levels of a molecule called perlecan, enabling cancer cells to spread throughout the body more easily. With a five-year survival rate of only 7% and a median survival of less than one year, pancreatic cancer is one of the most aggressive forms of cancer and frequently remains undetected until after it has spread. There is a need to dev...
Continue reading

Higher Fasting Glucose Increases Pancreatic Cancer Risk

Researchers have identified a link between elevated blood sugar levels and incidence rates of pancreatic cancer. With a five-year survival rate of only 9%, pancreatic cancer is not easily diagnosed and frequently remains undetected until after it has spread, resulting in an average of 45,750 deaths per year. While diabetes is a known risk factor, the connection between increased pancreatic cancer rates and elevated glucose levels in pre- and non-diabetic patients had not been identified until no...
Continue reading

Predicting Relapse in Pancreatic Neuroendocrine Tumors

Researchers have found a new way to classify non-functional pancreatic neuroendocrine tumors (PNETs) in order to predict which patients will experience relapse. Most PNETs are non-functional, meaning that they do not release excess hormones into the bloodstream. In current practice, patients whose non-functional PNETs are larger than 2 cm are considered at the highest risk of metastatic recurrence following surgery. "As clinical behaviors [of non-functional PNETs] vary widely and distant metasta...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.